LEPROSY

January, 2005

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

 

11046.  Soysal A, Atay T, Ozu T, Arpaci B. Electrophysiological evaluation of peripheral and autonomic involvement in leprosy. Can J Neurol Sci. 2004 Aug;31(3):357-62.

Pathogenesis:

11047.  Kang TJ, Yeum CE, Kim BC, You EY, Chae GT. Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Immunology. 2004 Aug;112(4):674-80.

 

                                                               Back

  
 

 

April, 2005

Therapy:

11541.       Rao NP. Recent advances in the control programs and therapy of leprosy. Indian Journal of Dermatology, Venereology and Leprology. 2004 Sep-Oct; 70(5): 269-276.

                                                               Back

  

 

July, 2005

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:

  1. Rohatgi J, Dhaliwal U, Singal A. Factors associated with sight threatening lesions of leprosy in patients on multidrug therapy. J Indian med Ass 2004, 102(6), 297-303.

  2. Siegmund V, Adjei O, Racz P, Berberich C, Klutse E, van Vloten F, Kruppa T, Fleischer B, Bretzel G. Dry-reagent-based PCR as a novel tool for laboratory confirmation of clinically diagnosed Mycobacterium ulcerans-associated disease in areas in the tropics where M. ulcerans is endemic. J Clin Microbiol. 2005 Jan;43(1):271-6.

Pathogenesis:

  1. You EY, Kang TJ, Kim SK, Lee SB, Chae GT. Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea. J Infect. 2005 Jan;50(1):6-11.

Vaccines:

  1. Zodpey SP, Ambadekar NN, Thakur A. Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, India. Public Health. 2005 Mar;119(3):209-16.

Therapy:

  1. Chirch LM, Jimenez VE. Lepromatous leprosy reversal reaction. Lancet Infect Dis. 2005 Jan;5(1):64.

                                                               Back

  

  October, 2005

Some Selected Abstracts:

1.

Matsuo E Leprosy as a challenge to science on the ability to decode its enigma. A hypothesis on how to respond. Jpn J Infect Dis. 2005 Apr;58(2):59-64.

Matsuo Medical Laboratory, Yokohama 227-0046, Japan. YIX11344@nifty.com

In world leprosy nowadays, a favorable epidemiologic trend has been provided due to the best effort of the worldwide campaign with chemotherapy providing a bright but one-sided look at the future. However, the numbers of new patients are still higher than those under chemotherapy, leaving a concern over the remaining non-human source of infection. To overcome that plausibility, overall understanding of the etiology of the disease should be improved. The author discussed this by the analyses of historical and scientific legitimacy of the current idea about the etiology of leprosy that have unreasonably rejected the possibility of dual infections in relation to that of Mycobacterium leprae. The analyses also consider the author's ongoing effort to know the feasibility of artificial culture of M. leprae by improving of the former methods reported by Skinsnes et al. and has been rejected as it contained Mycobacterium scrofulaceum, without attention to the coexistent M. leprae at that time. The bacillus thus maintained with the modification of the medium still shows PGL-1 immunoreactivity and the pathogenicity to cause neuropathy in mice. These strongly suggest the coexistence of the above two bacilli throughout past years. The genomic study is in progress to prove that hypothesis, the genomes should be alike in nature if proven.

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:

12746.  Banerjee S. Reconstruction of facial deformities in leprosy patients. J Indian Med Ass 2004; 102(12):700-1.

12747.   Biswas SK. Chemotherapy of leprosy. J Indian Med Ass 2004; 102(12):695-8.

12748.  Ganapati R, Pai VV. Reactions and their management. J Indian Med Ass 2004;102(12): 688-94.

12749.  Krishna Murthy P. Clinical manifestations, diagnosis and classification of leprosy. J Indian Med Ass 2004;102(12):678-9.

12750.  Lefmann M, Moter A, Schweickert B, Gobel UB. Misidentification of ycobacterium leprae as Mycobacterium intracellulare by the COBAS AMPLICOR M. ntracellulare test. J Clin Microbiol. 2005 Apr;43(4):1928-9.

12751.  Ramadasan P, Das AL, Patra AK. Effect of BCG Vaccination on evolution of leprosy. Medical Journal Armed Forces India. 2005 Jan; 61(1): 26-28.

Pathogenesis:

12752.  Andersson AK, Chaduvula M, Atkinson SE, Khanolkar-Young S, Jain S, Suneetha L, Suneetha S, Lockwood DN. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun. 2005 Jun;73(6):3725-33.

12753.  Grimm D. Microbiology. Global spread of leprosy tied to human migration. Science. 2005 May 13;308(5724):936-7.

12754.  Maeda Y, Mukai T, Spencer J, Makino M. Identification of an Immunomodulating Agent from Mycobacterium leprae. Infect Immun. 2005 May;73(5):2744-50. Erratum in: Infect Immun. 2005 Jul;73(7):4458.

12755.  Matsuo E. Leprosy as a challenge to science on the ability to decode its enigma. A hypothesis on how to respond. Jpn J Infect Dis. 2005 Apr;58(2):59-64. Review.

12756.  Monot M, Honore N, Garnier T, Araoz R, Coppee JY, Lacroix C, Sow S, Spencer JS, Truman RW, Williams DL, Gelber R, Virmond M, Flageul B, Cho SN, Ji B, Paniz-Mondolfi A, Convit J, Young S, Fine PE, Rasolofo V, Brennan PJ, Cole ST.  On the origin of leprosy. Science. 2005 May 13;308(5724):1040-2.

12757.  Wilkinson RJ, Lockwood DN. Antigenic trigger for type 1 reaction in leprosy. J Infect. 2005 Apr;50(3):242-3.

Therapy:

12758.  Bakker MI, Hatta M, Kwenang A, Van Benthem BH, Van Beers SM, Klatser PR, Oskam L. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J Trop Med Hyg. 2005 Apr;72(4):443-8.

12759.  Kar BR, Ebenezer G, Job CK. Penile tuberculoid leprosy in a, five year old boy. Indian Journal of Dermatology, Venereology and Leprology. 2005 Mar-Apr; 71(2): 125-127.

12760.  Kuldeep CM, Mittal AK, Gupta LK, Paliwal VK, Sharma P, Garg A. Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy (letter). Indian Journal of Dermatology, Venereology and Leprology. 2005 Jan-Feb; 71(1): 44.

12761.  Villahermosa LG, Fajardo TT Jr, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer JP, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am J Trop Med Hyg. 2005 May;72(5):518-26.

                                                               Back